Resmetirom Side Effects: What Patients and Clinicians Need to Know

What Is Resmetirom and Why Does Its Side-Effect Profile Matter?

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist approved by the FDA in March 2024 under the brand name Rezdiffyne. It targets liver-specific THR-beta receptors to reduce hepatic fat without the cardiac or bone effects associated with systemic thyroid hormone activity. For the estimated 16 million Americans with MASH, it is the only drug holding an FDA indication for histological improvement of liver fibrosis. Understanding what adverse effects to expect, at what rates, and how they compare with competing therapies helps patients and prescribers make informed decisions rather than stopping treatment prematurely.

The MAESTRO-NASH trial, the phase 3 study that supported FDA approval, enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1 to F3 and randomized them to 80 mg resmetirom, 100 mg resmetirom, or placebo for 52 weeks [1]. That single trial provides most of the safety data available today.

Most Common Resmetirom Side Effects: Gastrointestinal

Gastrointestinal events are by far the most frequently reported adverse effects with resmetirom. In MAESTRO-NASH, diarrhea occurred in 29% of patients receiving 100 mg and 25% of patients receiving 80 mg, compared with 17% on placebo [1]. Nausea was reported in 26% and 21% of the 100 mg and 80 mg groups, respectively, versus 14% in the placebo arm. Vomiting affected approximately 11% of patients in the 100 mg group.

These numbers look large, but context matters. Most events were graded as mild to moderate. The majority resolved on their own within the first four weeks without dose adjustment [1]. Prescribers typically advise patients to take the tablet with a meal, since food slows gastric emptying and may reduce peak drug concentration in the upper gut. Splitting the dose is not part of the current label guidance, so clinical management focuses on reassurance and dietary modification during the first month.

The FDA's prescribing information for Rezdiffyne confirms that GI events were the most common reason for treatment discontinuation, accounting for roughly 4% of discontinuations in the 100 mg group [2]. That rate remained low enough that the FDA considered it acceptable for the severity of the target disease.

Serious Adverse Events: What MAESTRO-NASH Found

Serious adverse event rates in MAESTRO-NASH were not statistically different between resmetirom and placebo arms [1]. No drug-related deaths occurred. Hepatic adverse events, including acute liver injury and elevation of liver enzymes above three times the upper limit of normal, were infrequent and did not cluster preferentially in the drug arms.

Cardiac safety deserves specific comment because THR-alpha stimulation is the main mechanism by which thyroid hormones accelerate heart rate and cause arrhythmias. Resmetirom was engineered for THR-beta selectivity, and MAESTRO-NASH found no statistically significant increase in heart rate, atrial fibrillation, or major adverse cardiac events compared with placebo [1]. The FDA label does not carry a cardiac black-box warning [2].

Gallbladder events, a concern with bile-acid modulating drugs, were not elevated above placebo rates. This distinguishes resmetirom from obeticholic acid, where increased rates of cholelithiasis have been observed in clinical programs [3].

Resmetirom vs. Obeticholic Acid: The Pruritus Problem

Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist that was studied extensively in MASH and primary biliary cholangitis (PBC). In the REGENERATE trial (N=2,477), dose-dependent pruritus occurred in 51% of the 25 mg OCA group and 28% of the 10 mg group, compared with 19% on placebo [3]. Pruritus was severe enough to cause 9% of patients on 25 mg to discontinue treatment [3].

The FDA declined to approve OCA for MASH in June 2023, citing an unfavorable benefit-risk assessment that included concerns about liver toxicity in patients with advanced fibrosis [4]. The pruritus signal alone was a major quality-of-life burden that influenced that decision. Resmetirom carries no clinically meaningful pruritus signal from its phase 3 data, making it a meaningfully different tolerability profile for patients already managing itching from cholestatic disease or other causes.

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance states: "Pruritus is a class effect of FXR agonists and must be discussed with patients prior to initiating therapy" [5]. Resmetirom, acting through a different mechanism, does not trigger this FXR-mediated itch pathway.

Resmetirom vs. Pioglitazone: Heart Failure and Weight Concerns

Pioglitazone, a PPAR-gamma agonist, has been used off-label for MASH for over a decade and is mentioned in multiple AASLD guidance documents [5]. It improves hepatic steatosis and inflammation, but its side-effect profile includes fluid retention, weight gain averaging 2 to 5 kg, and a well-documented increase in heart failure hospitalization risk.

The FDA label for pioglitazone carries a black-box warning stating that the drug "may cause or exacerbate congestive heart failure in some patients" and is contraindicated in patients with established New York Heart Association Class III or IV heart failure [6]. A meta-analysis of 19 randomized trials (N=16,390) found that pioglitazone increased the risk of edema by 67% and heart failure hospitalization by approximately 30% compared with control groups [7].

Given that MASH frequently coexists with type 2 diabetes, obesity, and cardiovascular disease, that heart failure signal is not trivial. Resmetirom, by contrast, produced no signal for fluid retention or weight gain in MAESTRO-NASH, and lipid data from the trial showed a 13% to 17% reduction in LDL-C at 100 mg, suggesting a potentially favorable cardiovascular risk direction [1]. This does not constitute a head-to-head cardiovascular outcomes trial, but the mechanistic and trial data point in different directions for these two agents.

Bone fractures are an additional concern with pioglitazone, particularly in postmenopausal women, where PPAR-gamma activation suppresses osteoblast differentiation [8]. No equivalent bone-loss signal appears in resmetirom's published data.

Lipid Changes: An Expected Pharmacological Effect, Not Toxicity

Because THR-beta drives hepatic LDL receptor expression and bile acid synthesis, resmetirom predictably lowers serum lipids. MAESTRO-NASH reported mean LDL-C reductions of 13.5% at 80 mg and 16.3% at 100 mg versus minimal change on placebo at week 52 [1]. Triglycerides fell by roughly 21% to 26% across dose groups.

These lipid changes are considered on-target pharmacology, not adverse events. Still, prescribers should be aware that patients already on high-intensity statins may see additive LDL-lowering. The clinical significance is favorable in most patients given that MASLD is associated with elevated cardiovascular mortality, but a small number of patients with unusually low baseline LDL-C may warrant monitoring.

The FDA label recommends no specific lipid monitoring beyond standard of care, but AASLD guidance suggests annual fasting lipid panels for patients with MASH given the underlying cardiometabolic risk [5].

Thyroid Function: Does Resmetirom Affect TSH?

A reasonable patient question is whether a thyroid receptor agonist will disrupt the hypothalamic-pituitary-thyroid axis. The answer, based on MAESTRO-NASH data, is: minimally [1]. Because resmetirom preferentially binds THR-beta in hepatocytes rather than THR-alpha in pituitary thyrotrophs, TSH suppression is not a class-wide concern at therapeutic doses.

In the trial, mean TSH levels were slightly reduced from baseline in resmetirom arms but remained within normal range for the majority of patients. Clinically significant hypothyroidism or hyperthyroidism attributable to the drug was not reported at rates above placebo [1]. The FDA label does note that thyroid function should be monitored in patients with pre-existing thyroid disease, and the drug should not be used in patients with decompensated hypothyroidism [2].

Patients on levothyroxine replacement should inform their prescriber before starting resmetirom, because the additive THR-beta activity could theoretically alter the adequacy of their existing dose.

Elevated Liver Enzymes: Signal or Noise?

Transaminase elevations are a concern with any hepatic drug given to patients who already have damaged livers. In MAESTRO-NASH, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) actually decreased in resmetirom-treated patients relative to placebo over 52 weeks, consistent with the drug's anti-steatotic and anti-inflammatory effects [1]. Drug-induced liver injury (DILI) meeting Hy's Law criteria was not reported in the active arms.

This is an important distinction from some earlier MASH drug candidates that triggered enzyme elevations severe enough to halt development programs. The FDA Hepatology Division specifically noted the absence of a hepatotoxicity signal when granting approval [2].

Baseline Child-Pugh score still matters. The current FDA label restricts use to patients with MASH and fibrosis stages F1 through F3. Patients with compensated cirrhosis (F4) were included in the MAESTRO-NASH-OLE (open-label extension) cohort, and additional safety data from that population are expected in late 2025.

Drug Interactions With Resmetirom

Resmetirom is a substrate of CYP3A4, CYP2C8, and P-glycoprotein. Strong CYP3A4 inhibitors such as clarithromycin or itraconazole may increase resmetirom plasma exposure; the label recommends avoiding concurrent use or using the lower 80 mg dose when co-administration cannot be avoided [2].

Statins merit attention. Resmetirom inhibits OATP1B1 and OATP1B3 transporters, which are responsible for hepatic uptake of several statins. In pharmacokinetic studies, rosuvastatin AUC increased approximately 4-fold when co-administered with resmetirom 100 mg, and simvastatin AUC increased roughly 3-fold [2]. The FDA label recommends limiting rosuvastatin to 20 mg daily and simvastatin to 20 mg daily when either is used alongside resmetirom. Atorvastatin exposure increased approximately 2-fold, and the label suggests a maximum atorvastatin dose of 40 mg daily in this setting [2].

These statin interactions are clinically meaningful because most patients with MASH are already on lipid-lowering therapy. Prescribers should review the complete statin co-medication list before initiating resmetirom and adjust doses as needed to avoid myopathy or rhabdomyolysis risk. A pharmacist-led medication reconciliation at treatment start is a practical safeguard.

Pregnancy, Lactation, and Reproductive Considerations

Animal studies with resmetirom showed fetal toxicity at exposures above those used clinically, leading to a Pregnancy Category warning in the FDA label [2]. Resmetirom should not be used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least five days after the last dose.

Data on excretion in human breast milk are unavailable. Given the potential for adverse effects in a nursing infant and the availability of alternative management strategies during lactation, breastfeeding is not recommended while taking this drug.

Male fertility data from animal studies did not demonstrate adverse effects on sperm parameters at clinical doses, but human reproductive data remain limited [2].

Managing Side Effects in Practice

Practical management of resmetirom GI side effects follows a straightforward sequence. Take the dose with food. If nausea persists beyond two weeks, a short-course anti-nausea agent such as ondansetron 4 mg as needed may reduce discomfort without compromising efficacy. If diarrhea is problematic, dietary review to reduce concurrent fat intake (which independently accelerates intestinal transit) often helps before reaching for loperamide.

The 80 mg dose produces slightly lower GI event rates than 100 mg (25% diarrhea vs. 29%, 21% nausea vs. 26%) [1]. For patients who cannot tolerate 100 mg, a prescriber could consider starting at 80 mg and re-assessing tolerability at week 4, though the FDA label does not formally designate 80 mg as a "starting" dose. Both doses showed histological benefit in MAESTRO-NASH, with the 100 mg dose achieving the primary endpoint for NASH resolution without worsening fibrosis in 26% of patients versus 9.7% for placebo (P<0.001) [1].

Comparing Side-Effect Burdens Across MASH Treatment Options

No head-to-head randomized trial has compared resmetirom, pioglitazone, and obeticholic acid directly. The available data come from separate trials with different populations, biopsy criteria, and follow-up durations, so indirect comparisons carry uncertainty. Still, the tolerability profiles are distinct enough to inform clinical decision-making.

Resmetirom's GI events are early-onset and self-limiting in most patients, and no cardiac, bone, or pruritus signals have emerged at 52 weeks [1]. Pioglitazone's fluid retention and weight gain are chronic effects that worsen over time in susceptible patients, and the heart failure risk is class-labeled [6]. Obeticholic acid's pruritus is dose-dependent, often persistent, and was cited by the FDA as part of an unfavorable benefit-risk profile for MASH [4].

For patients with pre-existing heart failure, pioglitazone is formally contraindicated, making resmetirom or another option necessary [6]. For patients with significant pruritus from another cause, adding OCA would likely be intolerable. These comparative tolerability features, combined with resmetirom's regulatory approval, have made it the first-choice pharmacological agent in most MASH treatment algorithms.

The AASLD 2023 Practice Guidance notes: "Weight loss of greater than or equal to 10% of body weight is associated with NASH resolution and fibrosis improvement, and lifestyle modification remains the foundation of MASLD management regardless of pharmacotherapy" [5]. Resmetirom does not replace weight loss; it addresses hepatic histology in patients for whom lifestyle modification alone has been insufficient.

A phase 3 cardiovascular outcomes extension (MAESTRO-NASH-OUTCOMES, currently enrolling) will provide harder data on myocardial infarction, stroke, and all-cause mortality over a five-year follow-up [9]. Results are expected in 2028.